CD138 has been shown to be an excellent antigen to be targeted by SSTNs as it plays a role in tumorigenesis together with insulin-like growth factor receptor (IGF-1R) type I and tumor-induced integrins αvβ3/αvβ5 (176, 177). This evidence concerns the gene IGF1R and neoplasm.